|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 574.30 CHF | -1.22% |
|
-1.41% | +6.81% |
| 15/07 | Lonza Reaffirmed at Outperform as RBC Notes Tight Supply, Demand in Biologics | MT |
| 14/07 | Swiss Market Index Slips; Roche Shares Down | MT |
Business description: Lonza Group AG
- biologics and bio-pharmaceuticals (55.9%): microbiological fermentation products, mammalian cell-based bio-pharmaceuticals, monoclonal antibodies, therapeutic proteins, etc.;
- synthesis products (24.7%): chemopharmaceutical products, bioconjugates, small molecules, active pharmaceutical ingredients, complex intermediates, etc.;
- specialised therapeutic products (15.8%): cell and gene therapies, synthetic therapeutic nucleic acids, oligonucleotides, microbial biological products, etc.;
- others (3.6%).
Number of employees: 20,000
Sales by Activity: Lonza Group AG
| Fiscal Period: December | 2021 (CHF) | 2022 (CHF) | 2023 (CHF) | 2024 (CHF) | 2025 (CHF) |
|---|---|---|---|---|---|
Integrated Biologics | 272.5Cr | 328Cr | 372.4Cr | 368Cr | 365.4Cr |
Advanced Synthesis | 77Cr | 82Cr | 90Cr | 98Cr | 161.7Cr |
Specialized Modalities | 65Cr | 74Cr | 76Cr | 74Cr | 110Cr |
Corporate/Eliminations | 4.2Cr | 11Cr | 17Cr | 11Cr | 16Cr |
Capsules & Health Ingredients | 122Cr | 126.9Cr | 116.2Cr | 105.5Cr | - |
Geographical breakdown of sales: Lonza Group AG
| Fiscal Period: December | 2021 (CHF) | 2022 (CHF) | 2023 (CHF) | 2024 (CHF) | 2025 (CHF) |
|---|---|---|---|---|---|
United States | 211.7Cr | 241.5Cr | 213.6Cr | 230.9Cr | 252.5Cr |
Switzerland | 66Cr | 100Cr | 116.8Cr | 72Cr | 96Cr |
Japan | 21Cr | 23Cr | 54Cr | 44Cr | 56Cr |
Belgium | 20Cr | 30Cr | 34Cr | 47Cr | 47Cr |
Ireland | 40Cr | 34Cr | 37Cr | 46Cr | 40Cr |
Germany | 20Cr | 22Cr | 30Cr | 30Cr | 24Cr |
Denmark | 13Cr | 16Cr | 32Cr | 28Cr | 24Cr |
Netherlands | 7.6Cr | 13Cr | 8.8Cr | 17Cr | 23Cr |
United Kingdom | 17Cr | 14Cr | 17Cr | 24Cr | 21Cr |
Sweden | 14Cr | 14Cr | 12Cr | 11Cr | 12Cr |
Singapore | 14Cr | 11Cr | 14Cr | 3.2Cr | 9.9Cr |
Puerto Rico | - | - | - | - | 9.7Cr |
South Korea | 7.9Cr | 14Cr | 9.7Cr | 12Cr | 9.6Cr |
China | 14Cr | 16Cr | 17Cr | 15Cr | 7.7Cr |
France | 9.7Cr | 12Cr | 11Cr | 11Cr | 4.2Cr |
Canada | 8.2Cr | 6.3Cr | 9Cr | 10Cr | 4.1Cr |
Rest of Europe | 22Cr | 21Cr | 20Cr | 18Cr | 3.2Cr |
Italy | 3.8Cr | 4.1Cr | 5.2Cr | 6Cr | 2.9Cr |
India | 4Cr | 4.2Cr | 4.2Cr | 4.6Cr | 1.5Cr |
Spain | 4.4Cr | 4.1Cr | 4Cr | 4.1Cr | 1.5Cr |
Rest of Asia | 3.1Cr | 3.6Cr | 2.9Cr | 2.8Cr | 80L |
Brazil | 6Cr | 4.9Cr | 7.1Cr | 4.9Cr | 50L |
Australia & New Zealand | 1.7Cr | 2.1Cr | 1.6Cr | 1.7Cr | 40L |
Czech Republic | 70L | 70L | 1.1Cr | 80L | 40L |
Other Countries | 10L | 20L | 20L | 30L | 30L |
Mexico | 3Cr | 3.4Cr | 3.3Cr | 3.1Cr | 20L |
Thailand | 1.7Cr | 1.5Cr | 1.5Cr | 1.2Cr | 10L |
Indonesia | 1.8Cr | 1.6Cr | 1.4Cr | 1.2Cr | - |
Rest of North and Central America | 10L | 10L | 10L | - | - |
Rest of Latin America | 4.7Cr | 3.8Cr | 2.6Cr | 8Cr | - |
Executive Committee: Lonza Group AG
| Manager | Title | Age | Since |
|---|---|---|---|
Wolfgang Wienand
CEO | Chief Executive Officer | 54 | 01/07/2024 |
Philippe Deecke
DFI | Director of Finance/CFO | 54 | 01/12/2021 |
Jason Berndt
COO | Chief Operating Officer | - | 01/10/2025 |
Daniel Buchta
IRC | Investor Relations Contact | - | - |
| Human Resources Officer | - | 01/11/2024 |
Composition of the Board of Directors: Lonza Group AG
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 57 | 08/05/2024 | |
Marion Helmes
BRD | Director/Board Member | 60 | 05/05/2022 |
Eric Drapé
BRD | Director/Board Member | 65 | 09/05/2025 |
David Meline
BRD | Director/Board Member | 69 | 09/05/2025 |
Juan Andres
BRD | Director/Board Member | 61 | 09/05/2025 |
Stephen Fry
BRD | Director/Board Member | 60 | 08/05/2026 |
Sami Atiya
BRD | Director/Board Member | 62 | 08/05/2026 |
| Director/Board Member | 59 | 08/05/2026 | |
Christoph Mäder
BRD | Director/Board Member | 67 | 26/04/2016 |
| Director/Board Member | 66 | 04/05/2018 |
Holdings: Lonza Group AG
| Name | Stocks | % | Valuation |
|---|---|---|---|
LONZA GROUP AG 0.55% | 3,84,792 | 0.55% | 260 M $ |
Company details: Lonza Group AG
Group companies: Lonza Group AG
| Name | Category and Sector |
|---|---|
Lonza India Pvt Ltd.
 Lonza India Pvt Ltd. Part of Lonza Group AG, Lonza India Pvt Ltd. is a contract development and manufacturing organization serving the healthcare industry with integrated solutions across biologics, small molecules, advanced synthesis, and specialized modalities such as cell and gene therapies, microbial products, and mRNA/LNP technologies. Lonza India specializes in complex bioconjugates, providing development and manufacturing services for antibody-drug conjugates, antibody oligonucleotide conjugates, and other bioconjugate modalities, utilizing advanced technologies and large-scale GMP facilities. The company is based in Mumbai, India. The Indian company offers end-to-end services from early drug development — including cell line development, protein engineering, and analytical method development — to clinical and commercial manufacturing of drug substances and products under cGMP conditions. The company also supports exosome characterization and manufacturing with proprietary engineering technology and high-yield biomanufacturing processes for exosome therapeutics. Its analytical services cover mammalian biologics and microbial products, offering validated methods for product characterization, stability testing, and batch release. Lonza India aligns its operations with United Nations sustainable development goals, focusing on environmental impact reduction, social responsibility, and ethical compliance. | |
Lonza Sales AG
 Lonza Sales AG Medical DistributorsDistribution Services Supplies pharmaceutical, biotech and specialty ingredients |
Medical Distributors
|
M.W. Encap Ltd.
 M.W. Encap Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for pharmaceutical preparations |
Pharmaceuticals: Major
|
Arch Chemicals Ltd.
 Arch Chemicals Ltd. Chemicals: SpecialtyProcess Industries Manufactures inorganic basic chemicals |
Chemicals: Specialty
|
Capsugel Spain SL
 Capsugel Spain SL Pharmaceuticals: MajorHealth Technology Develops, promotes and distributes empty gelified and polymer capsules |
Pharmaceuticals: Major
|
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.22% | -1.41% | +0.81% | +6.13% | 5.03TCr | |
| -1.30% | -4.38% | +375.91% | +586.77% | 3.92TCr | |
| +2.35% | +0.96% | +32.99% | -4.69% | 3.45TCr | |
| +3.02% | +4.51% | +13.37% | +59.92% | 3.46TCr | |
| +1.68% | -0.62% | +3.30% | +27.34% | 2.7TCr | |
| -0.72% | -3.51% | - | - | 1.67TCr | |
| +1.31% | -0.21% | +69.74% | +116.04% | 1.51TCr | |
| -0.14% | +0.58% | +14.46% | +17.81% | 1.39TCr | |
| -0.06% | +2.07% | +19.60% | -29.70% | 1.32TCr | |
| -0.83% | -2.04% | +1,328.06% | +655.35% | 1.18TCr | |
| Average | +0.45% | +0.66% | +206.47% | +159.44% | 2.56TCr | |
| Weighted average by Cap. | +0.42% | +0.70% | +140.48% | +147.35% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LONN Stock
- Company Lonza Group AG
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition